Characterization of rare transforming KRAS mutations in sporadic colorectal cancer

Joanna HM Tong1,2,3, Raymond WM Lung1,2,3, Frankie MC Sin1,2,3, Peggy PY Law1,2,3, Wei Kang1,2,3, Anthony WH Chan1, Brigette BY Ma4,5, Tony WC Mak6, Simon SM Ng2,3,6, and Ka Fai To1,2,3,*

1Department of Anatomical and Cellular Pathology; State Key Laboratory in Oncology on South China; Prince of Wales Hospital; The Chinese University of Hong Kong; Hong Kong SAR, PR China; 2Institute of Digestive Disease; Partner State Key Laboratory of Digestive Disease; The Chinese University of Hong Kong; Hong Kong SAR, PR China; 3Li Ka Shing Institute of Health Science; Hong Kong SAR, PR China; Sir Y.K. Pao Cancer Center; Hong Kong SAR, PR China; 4Department of Clinical Oncology; The Chinese University of Hong Kong; Hong Kong SAR, PR China; 5Department of Surgery; The Chinese University of Hong Kong; Hong Kong SAR, PR China; 6Department of Surgery; The Chinese University of Hong Kong; Hong Kong SAR, PR China

Keywords: colorectal cancer, KRAS, targeted therapy
Abbreviations: mCRC, metastatic colorectal carcinoma; mAbs, monoclonal antibodies; EGFR, epidermal growth factor receptor; FFPE, formalin-fixed, paraffin-embedded

KRAS mutational status has been shown to be a predictive biomarker of resistance to anti-EGFR monoclonal antibody (mAb) therapy in patients with metastatic colorectal cancer. We report the spectrum of KRAS mutation in 1506 patients with colorectal cancer and the identification and characterization of rare insertion mutations within the functional domain of KRAS. KRAS mutations are found in 44.5% (670/1506) of the patients. Two cases are found to harbor double mutations involving both codons 12 and 13. The frequencies of KRAS mutations at its codons 12, 13, 61, and 146 are 75.3%, 19.3%, 2.5%, and 2.7%, respectively. The most abundant mutation of codon 12 is G12D, followed by G12V and G12C while G13D is the predominant mutation in codon 13. Mutations in other codons are rare. The KRAS mutation rate is significantly higher in women (48%, 296/617) than in men (42.1%, 374/889, P = 0.023). Tumors on the right colon have a higher frequency of KRAS mutations than those on the left (57.3% vs. 40.4%, P < 0.0001). Two in-frame insertion mutations affect the phosphate-binding loop (codon 10–16) of KRAS are identified. One of them has never been reported before. Compared with wild-type protein, the insertion variants enhance the cellular accumulation of active RAS (RAS-GTP) and constitutively activate the downstream signaling pathway. NIH3T3 cells transfected with the insertion variants show enhanced anchorage-independent growth and in vivo tumorigenicity. Potentially these mutations contribute to primary resistance to anti-EGFR mAb therapy but the clinical implication requires further validation.

Introduction

Colorectal cancer (CRC) is one of the most common lethal cancers worldwide. In 2008, more than 1.2 million new cases were diagnosed, with approximately 608,700 deaths estimated to have occurred.1 Epidermal growth factor receptor (EGFR), a critical molecule in CRC initiation and progression, is frequently overexpressed in metastatic CRC (mCRC) tumors.2,3 The phenomena lead to the development of molecular targeting therapy to inhibit the EGFR signaling pathway. Using anti-EGFR monoclonal antibodies (mAbs) such as cetuximab and panitumumab, have been approved in treating mCRC to inhibit EGFR activity and hence switching off downstream pathways.2,3

However, anti-EGFR therapy does not work on all CRCs, largely due to the resistance to the anti-EGFR mAbs.4 Different studies have reported the response and outcome of CRCs to the anti-EGFR mAbs was poor with KRAS mutation which accounting for 30–40% of non-responsive cases.4–7 KRAS mutation status is now considered to be a predictive biomarker of resistance to anti-EGFR mAbs treatment for mCRC patients. KRAS is one of the RAS superfamily of proto-oncoproteins which is small signal switch molecule called GTPase, cycling between inactive GDP-bound (RAS-GDP) and active GTP-bound (RAS-GTP) forms, to regulate cellular growth and differentiation.8 Activating mutations of RAS proto-oncogenes continuously elevate the cytoplasmic RAS-GTP level. Oncogenic signaling pathways, such as Raf-MEK-ERK and PI3K/AKT cascades, are then constitutively activated in an EGFR activation-independent manner and therefore promote cell cycle progression.5,8 KRAS mutation is found in 40% of CRCs and missense point mutation is the most common mutation. The majority of the point mutation sites of KRAS in CRC patients are located at codons 12 and 13 (~80% and ~17%, respectively), together with rare mutations at codons 61 and 146 (~1–4%).3,8–11

Most clinical studies of KRAS mutation in CRC were conducted in western countries. However, KRAS mutation rate or spectrum in CRCs may partially depends on the population studied.12 It has been reported that KRAS mutations were

*Correspondence to: Ka Fai To; Email: kfto@cuhk.edu.hk
Submitted: 09/25/2013; Revised: 03/10/2014; Accepted: 03/16/2014; Published Online: 03/18/2014
http://dx.doi.org/10.4161/cbt.28550
identified in CRC patients from the UK, Switzerland, and Spain, for 27.4%, 38%, and 41% respectively. This epidemiological variation indicates the establishment of a local CRC KRAS mutation data in different populations. There has been a dramatic increase in reported incidence of colorectal cancer in Asian. It is of paramount importance to investigate the KRAS mutation spectrum in our locality in view of the implication in using anti-EGFR targeting therapy. We aim to analyze the KRAS mutation status and the clinical correlation in Chinese patients with CRC in Hong Kong. Here we report the spectrum of KRAS mutation in a large cohort of colorectal cancer and the identification and characterization of a novel insertion mutation within the function domain of KRAS.

Results
Clinical characteristics of the patients
We tested a total of 1506 patients with colorectal cancer. Of them 889 (59%) were males and 617 (41%) were females. The median age at presentation was 61 ± 11.3 (range 21–89 y). The clinical characteristics were in keeping with other reported populations of colorectal cancer. The age of female patients were slightly younger than males (59 ± 12.1 vs 61 ± 11.2, P = 0.014). There was significantly higher frequency of left colon tumor (75.8%) than the right side (24.2%, P < 0.0001). However, the right side tumors were more common in females (28.7%) compared with males (21.1%, P = 0.001). When rectal tumor was considered a separate entity, female patients had a higher frequency of right side tumor whereas the rectal tumors were more commonly found in male patients (P < 0.0001). The clinical characteristics of the patients tested were summarized in Table 1.

Status of KRAS mutation
KRAS mutations on codons 12, 13, 61 and 146 were analyzed by PCR-direct sequencing using microdissected FFPE tumor tissues from 1506 patients. A total of 672 KRAS mutations were identified from 670 colorectal tumors. A total of 672 KRAS mutations were detected from 670 colorectal tumors.

Table 1. Clinical characteristics of 1506 patients tested for KRAS status

| n     | Female | Male | P value |
|-------|--------|------|---------|
| Age   | 61 ± 11.3 | 61 ± 11.2 | 0.014   |
| Tumor site (right vs left) | 177 (28.7%) | 188 (21.1%) | 0.001   |
| Right | 365 (24.2%) | 177 (28.7%) | 188 (21.1%) | 0.0001  |
| Left  | 1141 (75.8%) | 440 (71.3%) | 701 (78.9%) | < 0.0001 |

Table 2. KRAS mutations spectrum in 670 colorectal cancers

| Mutation | Frequency | Percentage |
|----------|-----------|------------|
| Codon 12 | G12D      | 252        | 37.5%     |
| G12V     | 135       | 20.1%      |
| G12C     | 46        | 6.8%       |
| G12S     | 33        | 4.9%       |
| G12A     | 29        | 4.3%       |
| G12R     | 10        | 1.5%       |
| Codon 13 | G13D      | 128        | 19.0%     |
| G13C     | 2         | 0.3%       |
| Codon 61 | 17        | 2.5%       |
| Q61H     | 9         | 1.3%       |
| Q61L     | 5         | 0.7%       |
| Q61K     | 1         | 0.1%       |
| Q61R     | 2         | 0.3%       |
| Codon 146| 18        | 2.7%       |
| A146T    | 18        | 2.7%       |
| Others   | 2         | 0.3%       |
| c.30_31insGGA,p.G10_A11insG | 1 | 0.1% |
| c.33_34insGGAGCT,p.A11_G12insGA | 1 | 0.1% |

* A total of 672 KRAS mutations were detected from 670 colorectal tumors. Two tumors harbored double mutations.

hepatic flexure, transverse, splenic flexure, descending, sigmoid, or rectum. If the tumors on the right side of the colon (ascending and transverse colon) were group together and compared with those on the left (splenic flexure to rectum), the frequency of KRAS mutations were significantly higher in the right colon (57.3% vs. 40.4%, P < 0.0001). The KRAS mutation was not associated with the age of the patient. In comparison of the most frequently mutated codons between left and right colon, codon 12

Table 1. Clinical characteristics of 1506 patients tested for KRAS status

| Mutation | Frequency | Percentage |
|----------|-----------|------------|
| Codon 12 | G12D      | 252        | 37.5%     |
| G12V     | 135       | 20.1%      |
| G12C     | 46        | 6.8%       |
| G12S     | 33        | 4.9%       |
| G12A     | 29        | 4.3%       |
| G12R     | 10        | 1.5%       |
| Codon 13 | G13D      | 128        | 19.0%     |
| G13C     | 2         | 0.3%       |
| Codon 61 | 17        | 2.5%       |
| Q61H     | 9         | 1.3%       |
| Q61L     | 5         | 0.7%       |
| Q61K     | 1         | 0.1%       |
| Q61R     | 2         | 0.3%       |
| Codon 146| 18        | 2.7%       |
| A146T    | 18        | 2.7%       |
| Others   | 2         | 0.3%       |
| c.30_31insGGA,p.G10_A11insG | 1 | 0.1% |
| c.33_34insGGAGCT,p.A11_G12insGA | 1 | 0.1% |

* A total of 672 KRAS mutations were detected from 670 colorectal tumors. Two tumors harbored double mutations.
mutations were significantly more likely to occur in rectum (right colon 28.8%, left colon 29.7%, rectum 41.6%), while codon 13 mutations were slightly more frequent in the right colon (right colon 40%, left colon 30.8%, rectum 29.2%, \( P = 0.013 \)).

Identification of rare \( \text{KRAS} \) insertion mutations

In the pool of CRC cases, we identified two rare \( \text{KRAS} \) mutations which were defined as in-frame insertion mutations. The Insertion mutations in \( \text{KRAS} \) exon 2 of patient #286 and #833 were further validated by direct sequencing of the cloned PCR products (Fig. 1). In patient #286, an in-frame insertion of 3-nucleotide (GGA) between codons 10 and 11 was observed (c.30_31insGGA: p.G10_A11insG). This rare mutation, which suggested the insertion of a glycine residue between glycine (amino acid 10) and alanine (amino acid 11), was reported once in the patient with myeloid leukemia. In patient #833, a tandem repeat sequences of codon 10 and 11 (GGA GCT) was in-frame inserted after codons 11 and introduced extra glycine and alanine residues between alanine (codon 11) and glycine (codon 12). This insertion mutation (c.33_34insGGAGCT:p.A11_G12insGA) has never been reported before. These two mutations are named 10G11 and 11GA12 respectively.

**Table 3. Correlation of \( \text{KRAS} \) mutation status with clinical features**

| Characteristics | \( \text{KRAS} \) mutation | Total | \( P \) value |
|-----------------|-----------------------------|-------|--------------|
|                 | +                          | -     |              |
| \( n = 1506 \)  | 670 (44.5%)                | 836   | (55.5%)      |
| No. cases       | 61.3 ± 11.3                | 60.5 ± 11.3 | NS           |
| Gender          | 296 (48%)                  | 321 (52%) | 617          |
|                 | 374 (42.1%)                | 515   | (57.9%)      |
| Age             | 62.1 ± 10.1                | 60.4 ± 9.0 | NS           |
| Tumor site (right vs left) | 209 (57.3%) | 156 (42.7%) | 365 | < 0.0001 |
| Right           | 461 (40.4%)                | 680   | (59.6%)      |
| Left            | 670                        | 836   | 1506         |
| Tumor site (right vs left vs rectum) | 209 (57.3%) | 156 (42.7%) | 365 | < 0.0001 |
| Right           | 198 (36.8%)                | 340   | (63.2%)      |
| Left            | 263 (43.6%)                | 340   | (56.4%)      |
| Rectum          | 670                        | 836   | 1506         |

**Figure 1. Electropherogram for \( \text{KRAS} \) mutants.** Tissue DNA from the patient with colorectal cancer were amplified and cloned for sequencing analysis. Two novel in-flame insertions (10G11 and 11GA12) in exon 2 of \( \text{KRAS} \) gene were identified.

**KRAS exon 2 insertions activate RAS signaling pathway and enhance NIH3T3 cells transformation**

To investigate whether the newly found 10G11 and 11GA12 \( \text{KRAS} \) mutation activate RAS activity, we constructed expression plasmids and transiently transfected into 293FT and NIH3T3 cells. As a control, expression plasmids carrying wild-type \( \text{KRAS} \) (\( \text{KRAS} \)-WT) and a well-known active \( \text{KRAS} \) mutant (\( \text{KRAS} \)-G12V) were used for comparison during the basic functional assay.

Compared with the cells transfected with WT expression plasmid, overexpression of 10G11 and 11GA12 \( \text{KRAS} \) mutants in cell lines resulted in elevated protein levels of both active RAS (Ras-GTP) and its downstream signaling molecule, phosphorylated extracellular signal-regulated kinase (p-ERK). The elevated levels of these two proteins are similar to the cells transfected with the \( \text{KRAS} \)-G12V mutant construct (Fig. 2). To further demonstrate the biological effect of 10G11 and 11GA12 \( \text{KRAS} \) mutants, NIH3T3 cells which stably transfected with empty vector, \( \text{KRAS} \)-WT, \( \text{KRAS} \)-G12V, 10G11 or 11GA12 mutant were prepared. Although NIH3T3 stable transfectants showed similar proliferation rate in MTT assay (data not shown), they have apparent differences
in anchorage-independent growth property. We demonstrated in soft-agar colony formation assay that only a few number of colonies of the cells transfected with either empty vector or KRAS-wild type expression vector were observed. In contrast, more colonies were counted in all three transfectants with mutant KRAS and the differences were statistically significant compared with cells transfected with KRAS-wild type (Fig. 3). Furthermore, the colony sizes of the mutant KRAS transfectants were, in general, bigger than that in KRAS-wild type transfectant. To assess the in vivo tumorigenicity of novel KRAS variants, NIH3T3 transfectants containing empty vector or different KRAS mutants were injected subcutaneously into the dorsal flank of Balb/c nude mice. Compared with KRAS wild type and empty vector controls, KRAS G12D and G12A significantly enhanced in vivo tumor growth as showed in Figure 4. Collectively, these observations suggested that both newly identified KRAS mutants could activate the Raf-MEK-ERK pathway by elevating RAS-GTP level and contribute in vitro and in vivo cell transformation.

**Discussion**

In the current study, we report the KRAS mutation frequency in a large cohort of patients with colorectal cancer in Hong Kong. KRAS mutation is found in 44.5% (670 out of 1506) of colorectal cancers. The mutation rate is similar to KRAS studies previously reported.

Table 4 summarized the KRAS mutation rates and the distribution of mutants in representative studies. Codon 12 is the most common KRAS mutation and the most frequently found mutation is G12D (35% of all mutations found). Our data demonstrate the predominance of KRAS-mutant carcinoma in right colon and in female patients. This is in keeping with some previous reports although other studies might not have demonstrated such relationship. The preference of site of KRAS mutation might be correlate with the different molecular pathways involved in right and left side colon CRCs. The right and left side colon cancers have been considered as distinct tumor entities because of their epidemiological, clinicopathologic, and molecular biologic features. Right side colon cancer was found to be associated with female, older age, advanced stage, and poorly differentiated mucinous histology. Higher rates of microsatellite instability and KRAS mutations were common molecular events found in right side colon cancer. Whereas the left side tumor were more common to be chromosomal unstable and harbor more TP53 mutation. The reason for the observed differences between left and right side colon adenocarcinoma remains unclear. It is likely to be multifactorial and complex including embryologic origin, and the effect of chemical and bacterial luminal microenvironments. Moreover, we have reported the predominant KRAS mutations in left colon are located in codon 12 and right colon in codon 13. This finding is different from a large population-based study which found significantly more codon-12 mutation cases in proximal (right colon) than distal (left colon) tumors (29.1% vs 20.5%; P < 0.01). Another study also showed rectosigmoid tumor (left colon) had the highest frequency of codon 13 mutations. There is no consistent trend, further study is necessary.

We report two rare in-frame insertion mutations in this study, c.30_31insGGA: p.G10_A11insG (duplication of codon 10) and c.33_34insGAGGCT:p.A11_G12insGA (duplication of codon 10–11). In-frame Insertion mutations in KRAS are rarely reported. Almost all reported KRAS in-frame insertions are tandem duplications. Three-nucleotide insertions resulting in codon 9, codon 10, and codon 12 duplications have been reported in colorectal cancer and leukemia. A Netherland cohort study found a duplication of six nucleotides in a colorectal tumor, leading to two additional amino acids added in codon 9 of KRAS. A 15-bp insertion in exon 3 that resulted in tandem duplication of codons 62–66 has been found in a case of primary lung adenocarcinoma. Another study also reported the identical 15-bp in-frame insertion mutation in a colorectal carcinoma.

Wild-type KRAS regulate cellular growth and differentiation by cycling between inactive GTP-bound form (Ras-GDP) and active GTP-bound form (Ras-GTP). Mutant KRAS is defective in intrinsic GTP hydrolysis. Therefore, it is accumulated in cells in active GTP-bound form, resulting in constitutive activation of downstream signaling through effector proteins. Both insertion mutations found in the current study (G12D and G12A) affect the phosphate-binding loop (codon 10–16) of KRAS. Our in vitro functional analyses have confirmed that similar to the KRAS mutant G12V, both rare mutants enhance the cellular accumulation of active RAS (Ras-GTP), and activate the Raf-MEK-ERK pathway. Using soft agar assays, we demonstrate the ability of both insertion variants in driving in vitro cell transformation.
We also show that both insertion mutants demonstrate enhanced tumorigenicity in nude mice. Our finding is concordant with previous in vivo analysis of \textit{KRAS} codon 12 mutation in acute leukemia which showed duplication of amino acid residue in codon 12 could lead to the activation of \textit{KRAS}. In addition, another RAS protein member, HRAS with an insertion mutation in codon 12 was reported to gain the ability in cell transformation. These results suggest that both point mutation and insertion mutation within codon 12 and sites nearby could activate RAS protein through interrupting the GTP binding site of RAS family protein.

In summary, this study has provided a \textit{KRAS} mutation database in colorectal cancer of local Chinese population and the correlation between \textit{KRAS} status with gender and primary site in the colon. Furthermore, we report the identification and characterization of two rare \textit{KRAS} insertion mutations. In vitro and in vivo functional studies confirm the oncogenic properties of these insertion mutations. \textit{KRAS} mutations beyond the “hotspots” can be oncogenic by conveying selective growth advantage to the cells. These mutations might potentially contribute to primary resistance for anti-EGFR mAb targeted therapy. The clinical implication for these mutations requires further validation.

**Materials and Methods**

**Patient sample**

A total of 1506 consecutive colorectal adenocarcinoma specimens sent for \textit{KRAS} mutational analysis in Prince of Wales Hospital, Hong Kong between 2008 and 2012 were included in this study. The study protocol was approved by the Joint CUHK-NTE Clinical Research Ethics Committee, Hong Kong.

**Tumor DNA extraction**

The location of tumor cells in the formalin-fixed, paraffin-embedded (FFPE) tissue were first marked on the standard H&E-stained histological slides. Subsequently, the corresponding tumor tissues on the unstained glass slide were microdissected manually for DNA extraction using QIAamp DNA tissue mini kit with standard procedure (Qiagen).

**Sequencing analysis**

Mutational hot spots including \textit{KRAS} codons 12, 13, 61, and 146 were investigated by PCR-direct sequencing. PCR reactions were performed using primers listed in Table 5. Cycling sequencing reaction of the PCR fragments was performed with BigDye Terminator system (Applied Biosystems) using primers from both directions. The sequencing results were analyzed with the ABI PRISM® 3130XL Genetic Analyzer (Applied Biosystems). The data was collected and analyzed using Applied Biosystems sequencing analysis software.

**Detection of the precise sequence of the rare mutation**

PCR product corresponding to \textit{KRAS} exon 1 was amplified from the patient genomic DNA and subsequently cloned using the TOPO-TA Cloning kit (Invitrogen). Ten colonies of each transformation were randomly selected for sequencing analysis.

**Cell culture and transfection**

Human embryonic kidney cells (293FT) and mouse embryonic fibroblast cells (NIH3T3) were obtained from Invitrogen and American Type Culture Collection (ATCC) respectively. Both cell lines were cultured in Dulbecco modified Eagle medium plus 10% FBS (Gibco, Invitrogen). Transfection of 293FT and NIH3T3 cells were performed using Lipofectamine™ LTX reagent (Invitrogen) following the manufacturer’s protocol.

**Site-direct mutagenesis and active RAS measurement**

Full-length of \textit{KRAS} cDNA was cut from pBabe K-Ras 12V vector (Addgene plasmid 12544) and cloned into pcDNA3.1 (+) expression vector (Invitrogen) via BamHI and XbaI restriction sites. Corresponding \textit{KRAS} mutations were introduced into the expression vector using QuickChange® II Site-Directed Mutagenesis Kit according to the manufacturer’s recommendations (Stratagene). The desired mutations in each construct were finally confirmed by direct sequencing. The primer sequences for mutagenesis were listed in Table 5. Ras Activation Assay Kit (Millipore) was used to measure the level of active RAS (RAS-GTP) after transient transfection of corresponding plasmid into
the cell lines. In brief, 0.5 mg of cell extract was immunoprecipitated with agarose beads containing human Ras Binding Domain (RBD, residues 1–149) of Raf-1. After washing, the beads were mixed with protein loading buffer and 10% of the mixture was electrophoresed by 12% SDS-PAGE for western blot analysis as previously described.38,39 The primary antibodies used were pan-RAS (RAS10, Millipore; 1:2000) and p-ERK1/2 (9102, Cell Signaling; 1:1000). HRP conjugated anti-mouse secondary antibody used was purchased from DAKO (1:20000 dilution).

Soft agar colony formation assay
NIH3T3 cells transfected with corresponding KRAS expression plasmids were selected in culture medium containing 400 μg/mL of G418 (Invitrogen) for one month before preparing colony formation assay. In the assay, culture medium containing 0.7% agarose was set as a bottom layer in 6-well dishes. A total of 3000 cells, which mixed with culture medium containing 0.35% agarose, were added over the bottom layer. After 25 d of incubation, colonies were stained with 0.005% crystal violet overnight and were counted under dissection microscope. Each experiment was performed in triplicate.

In vivo tumorigenicity
NIH3T3 transfectants (1 × 10⁶ cells suspended in 0.1 mL phosphate-buffered saline), containing empty vector or different KRAS mutant, were injected subcutaneously into the dorsal flank of five 5-wk-old male Balb/c nude mice. The tumor volume was determined as previously described.40 All experimental procedures were approved by the Animal Ethics Committee of the Chinese University of Hong Kong.

Statistical analysis
Statistical analysis of two times two contingency tables of categorical variables was performed using the Chi-square test or Fisher exact test, as appropriate. The t test was performed to compare continuous variables between two groups. All statistical analyses were performed by using statistical program SPSS.
version 16.0. A two-tailed $P$ value of $<0.05$ was regarded as statistically significant.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.
38. Tong JH, Ng DC, Chau SL, So KK, Leung PP, Lee TL, Lung RW, Chan MW, Chan AW, Lo KW, et al. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010; 10:253; PMID:20525238; http://dx.doi.org/10.1186/1471-2407-10-253

39. Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL, Chan AW, Ng EK, Lo KW, To KF. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009; 11:1174-84; PMID:19881953

40. Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, et al. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 2011; 17:2130-9; PMID:21346147; http://dx.doi.org/10.1158/1078-0432.CCR-10-2467

41. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 2012; 18:9753-65; PMID:22753589; http://dx.doi.org/10.1158/1078-0432.CCR-11-3210

42. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeris KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753-62; PMID:20619739; http://dx.doi.org/10.1016/S1470-2045(10)70130-3

43. Chang YS, Yeh KT, Chang TJ, Chai C, Lu HC, Hsu NC, Chang JG. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 2009; 9:179; PMID:19515263; http://dx.doi.org/10.1186/1471-2407-9-179

44. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/NEJMoa0804385